Medicus, Vol. 21 No. 1_UGI, 2012.
Original scientific paper
A Switch Therapy Protocol with Intravenous Azithromycin and Ciprofloxacin Combination for Severe, Relapsing Chronic Bacterial Prostatitis: a Prospective Non-comparative Pilot Study
Adela Kolumbić Lakoš
; Pliva Croatia Ltd.
Višnja Škerk
; University Hospital for Infectious Diseases “Dr. Fran Mihaljević”, Zagreb, Croatia
Gordan Maleković
; Pliva Croatia Ltd.
Tatjana Dujnić Špoljarević
; Pliva Croatia Ltd.
Dražen Kovačić
; Pliva Croatia Ltd.
Miram Pasini
Alemka Markotić
; 2University Hospital for Infectious Diseases “Dr. Fran Mihaljević”, Zagreb, Croatia
Vittorio Magri
; Urology and Sonography Secondary Care Clinic, Azienda Ospedaliera Istituti Clinici di Perfezionamento, Milano, Italy
Gianpaolo Perletti
; Laboratory of Toxicology and Pharmacology, Department of Biomedical Inf./Env./ Comm. Sciences, Università degli Studi dell’Insubria, Busto A./Varese, Italy
Abstract
Chronic bacterial prostatitis (CBP) is characterized by intense clinical symptoms, frequent relapse episodes and poor quality of life. Aggressive antibacterial therapy is warranted to eradicate causative pathogens and to achieve a permanent cure. We administered a “switch-therapy” protocol to 30 patients showing severe CBP symptoms and two or more relapse episodes in the previous 12 months. Patients received intravenous azithromycin (500 mg/day) and ciprofloxacin (800 mg/day) for three days, followed by oral ciprofloxacin (1 g/day) for 25 days. Twenty-seven (90%) patients showed pathogen eradication at test-of-cure (TOC) visit. Five cases of infection relapse were detected at follow-up. At the TOC visit, 25 patients (83%) showed mild/absent symptoms, measured with the NIH-chronic prostatitis symptom index. These results indicate the efficacy of a “switch-therapy” protocol, based on combined azithromycin and ciprofloxacin. Comparative studies on larger CBP patient populations are warranted to confirm these encouraging results.
Keywords
chronic prostatitis; chronic bacterial prostatitis; chronic pelvic pain syndrome; macrolide; fluoroquinolone; genitourinary infections; azithromycin; ciprofloxacin; NIH-CPSI
Hrčak ID:
89366
URI
Publication date:
23.1.2012.
Visits: 1.550 *